Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

Medicine name and product details

Dupilumab (Dupixent, Sanofi) is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signalling. It is licensed as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils in adults who are taking an inhaled corticosteroid plus a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), or a LABA and a LAMA if inhaled corticosteroids are not appropriate. It is administered by subcutaneous injection. The details of the licensed indication and dosage schedule are available in the summary of product characteristics for dupilumab.